PURPOSE: CYT997 is a novel microtubule inhibitor and vascular disrupting agent. This phase I trial examined the safety, tolerability, pharmacokinetics and vascular-disrupting effects of orally-administered CYT997. EXPERIMENTAL DESIGN: We performed a phase I accelerated dose-escalation study of CYT997 given orally once every 2 to 3 weeks in patients with advanced solid tumours. Vascular disruption was assessed by measurement of plasma von Willebrand factor (vWF) levels and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). RESULTS: A total of 56 doses were administered to 21 patients over 8 dose levels (15-164 mg/m(2)). Grade 3 fatigue and grade 3 hypoxia were dose limiting. Oral bioavailability was observed with approximate linear pharmacokinetics over the 11-fold dose range. At doses of 84 mg/m(2) and above, plasma vWF levels increased above baseline and DCE-MRI scans showed reductions in tumour K(trans) in some patients. CONCLUSIONS: CYT997 is orally bioavailable. The 118 mg/m(2) dose level should be used to guide dosing in future studies.
PURPOSE: CYT997 is a novel microtubule inhibitor and vascular disrupting agent. This phase I trial examined the safety, tolerability, pharmacokinetics and vascular-disrupting effects of orally-administered CYT997. EXPERIMENTAL DESIGN: We performed a phase I accelerated dose-escalation study of CYT997 given orally once every 2 to 3 weeks in patients with advanced solid tumours. Vascular disruption was assessed by measurement of plasma von Willebrand factor (vWF) levels and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). RESULTS: A total of 56 doses were administered to 21 patients over 8 dose levels (15-164 mg/m(2)). Grade 3 fatigue and grade 3 hypoxia were dose limiting. Oral bioavailability was observed with approximate linear pharmacokinetics over the 11-fold dose range. At doses of 84 mg/m(2) and above, plasma vWF levels increased above baseline and DCE-MRI scans showed reductions in tumour K(trans) in some patients. CONCLUSIONS: CYT997 is orally bioavailable. The 118 mg/m(2) dose level should be used to guide dosing in future studies.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Christopher J Burns; Emmanuelle Fantino; Ian D Phillips; Stephen Su; Michael F Harte; Patricia E Bukczynska; Mark Frazzetto; Max Joffe; Irma Kruszelnicki; Bing Wang; Yue Wang; Neil Wilson; Rodney J Dilley; Soo S Wan; Susan A Charman; David M Shackleford; Rosa Fida; Cathy Malcontenti-Wilson; Andrew F Wilks Journal: Mol Cancer Ther Date: 2009-11-03 Impact factor: 6.261
Authors: Christopher J Burns; Emmanuelle Fantino; Andrew K Powell; Steven D Shnyder; Patricia A Cooper; Stuart Nelson; Christopher Christophi; Cathy Malcontenti-Wilson; Valentina Dubljevic; Michael F Harte; Max Joffe; Ian D Phillips; David Segal; Andrew F Wilks; Gregg D Smith Journal: J Pharmacol Exp Ther Date: 2011-09-14 Impact factor: 4.030
Authors: Wim Ceelen; Peter Smeets; Walter Backes; Nancy Van Damme; Tom Boterberg; Pieter Demetter; Isabel Bouckenooghe; Marieke De Visschere; Marc Peeters; Piet Pattyn Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-02 Impact factor: 7.038
Authors: Patricia M LoRusso; Shirish M Gadgeel; Antoinette Wozniak; Alan J Barge; Helen K Jones; Zachary S DelProposto; Pamela A DeLuca; Jeffrey L Evelhoch; Scott A Boerner; Catherine Wheeler Journal: Invest New Drugs Date: 2008-01-25 Impact factor: 3.850
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Colin J Mooney; Govardhanan Nagaiah; Pingfu Fu; Jay K Wasman; Matthew M Cooney; Panos S Savvides; Joseph A Bokar; Afshin Dowlati; Ding Wang; Sanjiv S Agarwala; Susan M Flick; Paul H Hartman; Jose D Ortiz; Pierre N Lavertu; Scot C Remick Journal: Thyroid Date: 2009-03 Impact factor: 6.568
Authors: Anne M Traynor; Michael S Gordon; Dona Alberti; David S Mendelson; Mark S Munsey; George Wilding; Richard E Gammans; William L Read Journal: Invest New Drugs Date: 2009-05-13 Impact factor: 3.850